1. Home
  2. GBX vs CRVS Comparison

GBX vs CRVS Comparison

Compare GBX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenbrier Companies Inc. (The)

GBX

Greenbrier Companies Inc. (The)

HOLD

Current Price

$51.78

Market Cap

1.8B

Sector

Industrials

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$15.34

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBX
CRVS
Founded
1974
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
GBX
CRVS
Price
$51.78
$15.34
Analyst Decision
Sell
Strong Buy
Analyst Count
2
5
Target Price
$49.00
$28.20
AVG Volume (30 Days)
214.1K
1.0M
Earning Date
04-06-2026
06-26-2026
Dividend Yield
2.44%
N/A
EPS Growth
28.02
48.04
EPS
1.14
N/A
Revenue
$3,240,200,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.64
N/A
P/E Ratio
$45.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.77
$2.54
52 Week High
$59.19
$26.95

Technical Indicators

Market Signals
Indicator
GBX
CRVS
Relative Strength Index (RSI) 35.21 42.27
Support Level $44.64 $6.65
Resistance Level $54.15 $18.73
Average True Range (ATR) 1.45 0.94
MACD -0.80 -0.29
Stochastic Oscillator 11.56 24.64

Price Performance

Historical Comparison
GBX
CRVS

About GBX Greenbrier Companies Inc. (The)

Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: